Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Syros Pharmaceuticals, Inc.
  6. Summary
    SYRS   US87184Q1076

SYROS PHARMACEUTICALS, INC.

(SYRS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
0.7696(c) 0.7774(c) 0.7101(c) 0.7(c) 0.7257(c) Last
1 079 658 731 057 807 466 1 008 831 712 072 Volume
-14.38% +1.01% -8.66% -1.42% +3.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 20,2 M - -
Net income 2022 -110 M - -
Net cash position 2022 30,2 M - -
P/E ratio 2022 -0,44x
Yield 2022 -
Sales 2023 16,0 M - -
Net income 2023 -135 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,37x
Yield 2023 -
Capitalization 45,6 M 45,6 M -
EV / Sales 2022 0,76x
Capi. / Sales 2023 2,86x
Nbr of Employees 124
Free-Float 93,8%
More Financials
Company
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefending the power of small molecules to control the expression of genes. The Company is engaged in developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical-stage pipeline of gene control medicine. The Company's lead product candidates... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/01 | 11:00amShareholder meeting
More about the company
Ratings of Syros Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about SYROS PHARMACEUTICALS, INC.
05/17HC Wainwright Adjusts Price Target on Syros Pharmaceuticals to $10 From $15, Reiterates..
MT
05/17Alliance Global Adjusts Price Target on Syros Pharmaceuticals to $10 From $14, Reiterat..
MT
05/16TRANSCRIPT : Syros Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 16, 2022
CI
05/16Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corpo..
BU
05/16SYROS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/16Syros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March ..
CI
05/16NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
05/09Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
BU
05/02Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
04/29Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
04/08Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Associat..
BU
04/08Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Progra..
CI
04/04Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
04/01Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
03/15TRANSCRIPT : Syros Pharmaceuticals, Inc., Q4 2021 Earnings Call, Mar 15, 2022
CI
More news
News in other languages on SYROS PHARMACEUTICALS, INC.
05/16Syros Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 ..
04/08Syros Pharmaceuticals, Inc. présente de nouvelles données précliniques sur son programm..
03/15Earnings Flash (SYRS) SYROS PHARMACEUTICALS affiche un chiffre d'affaires de 7,8 millio..
03/15Syros Pharmaceuticals, Inc. annonce ses résultats pour le quatrième trimestre et l'anné..
03/15Syros Pharmaceuticals, Inc. Le vérificateur remet en question la continuité de l'exploi..
More news
Analyst Recommendations on SYROS PHARMACEUTICALS, INC.
More recommendations
Chart SYROS PHARMACEUTICALS, INC.
Duration : Period :
Syros Pharmaceuticals, Inc. Technical Analysis Chart | SYRS | US87184Q1076 | MarketScreener
Technical analysis trends SYROS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 0,73 $
Average target price 14,00 $
Spread / Average Target 1 829%
EPS Revisions
Managers and Directors
Nancy A. Simonian President, Chief Executive Officer & Director
Jason Haas Chief Financial Officer
Peter Wirth Chairman
Eric R. Olson Chief Scientific Officer
David A. Roth Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SYROS PHARMACEUTICALS, INC.-77.74%46
MODERNA, INC.-46.35%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.46%38 185
SEAGEN INC.-9.68%26 255
ICON PUBLIC LIMITED COMPANY-30.22%17 418